Anti-drug antibody news

What is the immunogenic profile of a drug and what to do about it? At Pharmetheus, we have, together with the whole team, reviewed with interest the new draft FDA guidance

On the QSP side, we are progressing with our contributions to the subcutaneous delivery platform, upon which Erik Sjögren will present at PAGE: A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework

When it comes to PKPD models, we are following the collaborative advances in Hidden Markov Modeling, with contributions by Elodie Plan: